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Background: Chronic graft-versus-host disease (cGVHD) is a major factor of morbidity and mortality for allogeneic
stem cell transplantation (aSCT). The skin and internal organ involvement is the most common systemic complication
of cGVHD and closely resembles systemic sclerosis (SSc). Circulating lymphocytes characterize the autoimmune nature
of both conditions. Therefore we hypothesized that the common clinical manifestation (systemic organ and skin injury)
and the common underlying players (lymphocytes) justify the combined meta-analysis of these diseases.
Results: The aSCT and SSc datasets were uploaded from Gene Expression Omnibus (GEO), a public functional genomics
data repository. The available microarray studies of peripheral blood mononuclear cells (PBMCs) and isolated lymphocytes
were limited to well established microarray platforms (Affymetrix, Agilent, Canvac, and Illumina) and experimental settings
with ≥10 patients per group. The resulting pools of data were merged by unique gene identifier and analyzed by the
expression genome-wide association studies (eGWAS) coupled with the subtraction of the cGVHD+ and cGVHD−
molecular signatures. The eGWAS was applied to 47 and 50 lymphocyte profiles from aSCT and SSc patients, respectively.
The identified 35 candidates were represented by 8 known cGVHD genes (including CXCR4, LTBR and PML) and 28 new
candidate genes (including SEPX1 and DNJGB1). The further mutual subtraction of cGVHD+ and cGVHD− candidates and
pathway analysis identified a list of 25 genes. Seven of these genes belong to the fibroblast development and function
pathway, consisting of the well known cGVHD genes CCND1, JUN, and FOS, and the new molecular targets MMP2, FOSB,
TNFAIP8, and DUSP1. These genes become primary candidates for a potential link of systemic effects of cGVHD and SSc.
Conclusions: We designed a new approach for meta-analysis by combining data from different diseases using common
clinical manifestation as a linker. This allowed us to power up the insufficient standalone meta-analysis of aSCT microarray
studies, by adding SSc samples to the data pool. This new method has successfully identified novel molecular targets for
systemic effects of both aSCT and SSc. We believe that this approach is generalizable and can be applied to an array of
diseases with common clinical manifestations.
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Allogeneic stem cell transplantation (aSCT) has become
a curative therapy for increasing numbers of diseases.
To date, it is the only successful cellular immunotherapy
for high-risk malignancies such as leukemia. In pediatrics,
it also offers curative therapy for nonmalignant blood
disorders such as thalassemia, immune dysregulation,
congenital bone marrow failure syndromes, inborn errors
of metabolism and autoimmune conditions [1]. However,
30-70% of aSCT cases develop cGVHD, which occurs
100 days after transplantation with median time to onset
of 4–6 months [2]. The precise mechanisms of cGVHD
are unknown and evaluation of global transcriptional
changes of reconstituted immune cells from aSCT patients
is a feasible approach for studying cGVHD [3]. For instance,
the transcript profiling of CD4+ and CD8+ lymphocytes
from donors for aSCT demonstrated that predictive
biomarkers for cGVHD can be detected [4].
Due to the paucity of microarray data for standalone
meta-analysis of cGVHD, we used similarities in systemic
responses between cGVHD and systemic sclerosis
(SSc) to link their microarray datasets [5,6]. The similarity
in systemic responses between cGVHD and SSc was
demonstrated in the experimental settings and was
attributed to the excessive activation of T and B cells
in both conditions [7].Therefore, we hypothesized that
the combined meta-analysis of both diseases would lead
to better understanding of systemic effects of circulating
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Figure 1 eGWAS for aSCT and SSc using a χ2 analysis. The significance
plotted against corresponding chromosomal location (x axis). P values for e
as the likelihood of finding repeated differential expression compared with
demonstrated a significant differential expression, of which 101 had the kn
threshold (P = 1.53 × 10−6). The gene symbols indicate genes that are most
circles represent genes that demonstrated significant changes in both diseases
of tested diseases. Underscored symbols indicate known cGVHD genes. * - genIn this study we combined publicly available datasets
for aSCT (with or without cGVHD) and SSc (diffuse
and limited) and analyzed them using a meta-analysis
technique.
Results and discussion
A total of 32671 genes were analyzed by eGWAS and 35
genes were identified as associated with both diseases,
while 77 genes were associated with SSc only. Genes
associated with aSCT alone were not detected (Figure 1
and Additional file 1) due to the low statistical power of
cGVHD data. These findings support our approach and
provided 35 potential candidates, which otherwise would
have been missed by conventional analysis.
Eight genes among these candidates were previously
linked to cGVHD (Figure 1), which demonstrated that
despite the amplification of cGVHD data with unrelated
but similar clinical conditions, we generated a feasible can-
didate list for cGVHD. The top candidate was lymphotoxin
beta receptor or TNFR superfamily, member 3 (LTBR)
with P = 1.73 × 10−13 (Figure 1). Concordantly, it was
recently reported that the expression of LTBR is elevated
in patients with cGVHD+ as compared to cGVHD−, and
that the application of lymphotoxin beta receptor-
immunoglobulin fusion protein in mouse model of cGVHD
is beneficial [8,9].
Given that eGWAS confirmed the feasibility of
combined meta-analysis of two different diseases with
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, P values, of each tested gene is expressed as − log10 (y axis) and
ach gene were calculated for 7 microarray datasets (4 aSCT and 3 SSc)
expected using χ2 analysis. Out of 32671 genes tested 118 genes
own chromosomal location. The dotted line indicates the Bonferroni
significantly associated with both clinical aSCT and SSc. The open
and the solid circles represent genes with significant changes only in one
es that were also detected by subtraction of ranking order gene lists.
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and SSc.
We began with stratified analysis of CD4+ and CD8+
T-cells from patients with cGVHD and identified 225
CD4+ and 155 CD8+ transcripts significantly affected by
the new host environment. The analysis of CD4+ and
CD8+ T-cells from patients who underwent aSCT and
remained cGVHD− one year later identified 800 and 241
transcripts with significant changes, respectively. 84
up- and 141 down-regulated cGVHD+ transcripts of
CD4+ lymphocytes were cross-referenced against 559
up- and 241 down-regulated aSCT transcripts (Figure 2A).
This approach identified 68 up- and 118 down-regulated
transcripts that were specific for cGVHD+. In addition, 24
transcripts were oppositely regulated in cGVHD+ and
cGVHD− CD4+ cells: 7 were up-regulated in cGVHD+,
but down-regulated in cGVHD− cells, and 17 were down-
regulated in cGVHD+, but up-regulated in cGVHD− cells
(Figure 2A), which add up to 210 cGVHD+ specific
transcripts in CD4+ cells. The similar cross-referencing of
CD8+ T-lymphocytes identified 94 up- and 50 down-
regulated transcripts that were specific for cGVHD+. In
addition, 2 transcripts were oppositely regulated in
cGVHD+ and cGVHD− CD8+ cells: one was up-regulated
in cGVHD+, but down-regulated in cGVHD− cells, and
another was down-regulated in cGVHD+, but up-regulated
in cGVHD− cells (Figure 2B), which were added up to 146
cGVHD+ specific transcripts in CD8+ cells.
The comparison of molecular changes of CD4+ and
CD8+ T-lymphocytes 1 year after aSCT was conducted by
chi-square test and demonstrated a significant difference
(P < 0.0001) in ratios of up- and down-regulated genes






















Figure 2 Detection of cGVHD specific transcripts in CD4+ and CD8+ ly
population of aSCT patients without cGVHD were subtracted from transcrip
subtraction was conducted by cross-referencing of transcriptional changes
Transcripts that are common to lymphocytes from control and cGVHD subsignature was shifted towards suppression of gene expres-
sion (75 up-regulated genes vs 135 down-regulated genes),
while in CD8+ T-cells the molecular signature was
shifted towards activation (95 up-regulated genes vs
51 down-regulated genes). The overall transcriptional
changes were more pronounced in CD4+ cells (210 genes)
versus CD8+ cells (146 genes). These findings suggested
that CD4+ plays a bigger role in aSCT than CD8+.
The cross-referencing transcripts associated with
cGVHD against transcripts associated with limited or
diffuse SSc identified 6 up-regulated genes (Figure 3A) and
19 down-regulated genes (Figure 3B) that were common to
both diseases, of which 4 genes were involved in limited
SSc and 21 were associated with diffuse SSc.
The significance of co-expression of these 25 genes
was evaluated by Student’s T-test. The contribution of
CD4+ lymphocytes to both cGVHD and SSc was 2.55
times higher (P = 0.033) than the contribution of CD8+
lymphocytes, which confirmed our observation of more
pronounced involvement of CD4+. We next tested
which type of SSc the molecular signature of cGVHD
lymphocytes most resembles. While we were able to
demonstrate that the molecular signature of cGVHD
lymphocytes resembles diffuse SSc by 2.2 fold more
than limited SSc, the t-test of this comparison did
not reach significance (p = 0.124).
The greater contribution of CD4+ to cGVHD molecular
signature was further confirmed by the pathway analysis.
We evaluated the relevance of cGVHD transcripts to
known biological processes using the Ingenuity Pathway
Analysis (IPA) tool (http://www.ingenuity.com). 163
out of 210 transcripts of CD4+ lymphocytes and 127 out
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ts that were up- or down- regulated in patients with cGVHD. The
in CD4+ (panel A) or CD8+ (panel B) lymphocytes, respectively.
jects were eliminated from further consideration.
AB
Figure 3 Cross-referencing cGVHD gene candidates with molecular signature of SSc. CD4+ (top) and CD8+ (bottom) lymphocytes were
cross-referenced against limited SSc or diffuse SSc, respectively. Transcripts that were upregulated (panel A) or downregulated (panel B) in both
cGVHD and scleroderma patients were considered to be associated with the skin manifestation of cGVHD.
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transcripts consisted of hypothetical proteins and
open reading frames.
The top three bioprocesses identified by IPA for CD4+
were connective tissue development and function, skeletal
and muscular system development and function, and
immune cell trafficking. These bioprocesses were built of
multiple functional subprocesses, where movement of
fibroblasts was the most significant function (Figure 4).
None of the top three bioprocesses identified by IPA for
CD8+ contained 5 or more genes, and therefore did not
pass filtering criteria.
The top three IPA pathways were overrepresented by
fibroblast related genes (7 genes). The immune cell
trafficking (5 genes), and muscle cell related functions
(4 genes) (Figure 5). While 8 out of 25 candidates
that we have detected were reported by the original
studies uploaded from GEO, the remaining 17 candidates
appeared to be missed as potential cGVHD candidates
(Figure 5).
These genes were unreported by the original studies,
most likely due to different goals and focuses of theauthors. This is an example of how the re-analysis of
publicly available data using new approaches will bring to
light molecular targets unsuspected by the original studies.
The same group of 25 genes was used for filtering
biological networks generated by IPA software. The
resulting network represented two major nodes built
of IL1B and JUN related molecular groups that were
cross-linked by FOSB-CCND1 node of fibrotic candidate
genes (Figure 6). The existing interactions between these
gene candidates suggest their common involvement in the
fibrotic response during cGVHD, thus further validating
our target selection.
PubMatrix analysis of 25 gene candidates common to
cGVHD and SSc identified 7 genes that were previously
linked to GVHD (Table 1). The analysis of mutually
subtracted cGVHD+ and cGVHD− genes identified 6
genes that were previously linked to GVHD, 3 of which
were linked to the fibroblast proliferation bioprocess
(Table 1). This suggests that our new genes identified by
these approaches will be also valid candidates for cGVHD.
Moreover, despite the completely different approaches
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Figure 4 Pathway analysis of cGVHD specific transcripts in CD4+ lymphocytes. 210 cGVHD transcripts were analyzed by the Ingenuity
Pathway Analysis (IPA) software. IPA mapped 163 of these transcripts to known genes and identified three major processes associated with
cGVHD: connective tissue development and function (solid bars), skeletal and muscular system development function (open bars), and immune cell
trafficking (hatched bars). The height of each bar represents − log10P value (y axis) of corresponding biological function (x axis). The dashed line
indicates the P value = 0.05 (−log10P = 1.301).
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by cross-referencing (Figure 5) were also among 35 genes
detected by eGWAS (Figure 1).
Of the remaining genes considered new candidates for
cGVHD, MMP2, FOSB, TNFAIP8, and DUSP1 were from
the fibroblast proliferation pathway and all, but TNFAIP8,
were assigned to the same gene-gene interaction networkFigure 5 Pathway distribution of cGVHD-SSc gene candidates.
The detailed output of pathway analysis was queried against 25
gene candidates (main circle), which are potentially associated with
the skin manifestation of cGVHD. Genes were grouped according to
involvement in three major pathways (Figure 5): connective tissue
development and function (solid oval), skeletal and muscular system
development function (dotted oval), and immune cell trafficking
(dashed oval). The known cGVHD genes are bolded. The candidates,
which were reported in the original aSCT study, are underscored. Genes
that were identified by our eGWAS studies (Figures 1) are highlighted
by grey boxes.(Figure 6). Moreover, amongst these genes, DUSP1 was
detected by eGWAS studies as well (Figure 1), therefore
DUSP1 became our primary candidate.
The expression of DUSP1 in lymphocytes had been
detected by many groups (18 citations), however, this
gene has not yet been implicated in aSCT or SSc
(Table 1). Despite this, the recent studies of circulating
cells in peripheral blood of kidney transplant patients
identified DUSP1 as a potential biomarker for monitor-
ing renal graft status [10]. We believe that results of our
meta-analysis and the reported allograft sensitivity of
DUSP1 warrants further studies of this gene in the
cGVHD setting.
The other new candidate, MMP2, had the strongest link
to aSCT (30 citations) and was detected in scleroderma
(2 citations). However it has not yet been linked to
cGVHD (Table 1 and Figure 5). In addition to its ability to
degrade extracellular matrix proteins, MMP2 can also act
on several nonmatrix proteins such as calcitonin gene-
related peptide, thus promoting vasoconstriction. Moreover,
its C-terminal non-catalytic fragment possesses an anti-
angiogenic property (http://www.uniprot.org). One can
speculate that the combination of vasoconstriction and
anti-angiogenisity can be contributory to hypoxia and sys-
temic sclerosis. Furthermore, the potential immunogenetic
role of MMP2 was observed in a mouse model of heart
transplant. It was demonstrated that alloreactivity of T-cells
was significantly lower in MMP2-deficient mice compared
to their wild type littermates [11]. All these findings make
MMP2 an extremely appealing target for cGVHD.
Our final candidate, FOSB, is less known in aSCT









Figure 6 The IPA network analysis of cGVHD-SSc gene candidates. Several networks were generated for 163 cGVHD candidate genes
significantly affected by new host environment in CD4+ lymphocytes. The top network is presented here and is limited to genes with direct
relationships with candidates for the skin manifestation of cGVHD. Relationships between genes are represented by solid lines (binding), solid
arrows (direct activation), or broken arrows (indirect activation). Arrows point to the element on which an action is performed. Black molecules
represent fibroblast related genes. Grey molecules represent other significant cGVHD genes.
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interaction analysis put this gene into the central
cross-linker nodule of two major nodes of cGVHD
candidates (Figure 6). The main function of FOSB is
believed to enhance binding activity of JUN proteins to
DNA. Furthermore, the finding that during induced clonal
anergy of CD4+ T-cells, JUN and FOS proteins, but not
FOSB, reduce their DNA-binding ability [12] makes FOSB
an interesting candidate that may prolong the active
state of T lymphocytes under suppressive conditions, thus
promoting the aSCT complications.
Conclusions
Presented here data indicate that: 1) for the first time
in the field of meta-analysis of microarray data we
conducted cross-disease analysis based on common
clinical manifestations; 2) CD4+ T-cells undergo more
pronounced changes during cGVHD than their CD8+
counterparts and these changes are shifted towards
down-regulation; 3) the molecular signature of cGVHD
does not demonstrate preferable similarity with either type
of systemic sclerosis; 4) the pathway analysis linked
expressional changes in lymphocytes from cGVHD
patients to fibroblast proliferation; 5) we identified 25
gene candidates common to both cGVHD and SSc, of
which primary candidates MMP2, FOSB, and DUSP1are
the most appealing for further studies. We believe that our
approach of in silico amplification of sparse microarray
data by linking molecular signatures of different diseases
with the same systemic complications and conductingmeta-analysis on such combined dataset is generalizable
and capable of detecting new molecular targets.
Methods
Data
The aSCT and SSc datasets were uploaded from gene
expression omnibus (GEO, NCBI, http://www.ncbi.nlm.
nih.gov/geo). The term “bone marrow transplant” was
submitted to the database query windows and this search
returned 81 entries (as of December 14, 2012), 23 of which
were data series, while the remaining data were either
annotation of microarray platforms or individual samples.
The inclusion criteria for retrieved data were the array
samples, which must: 1) represent genome wide studies
of human peripheral blood mononuclear cells (PBMCs)
or isolated lymphocytes; 2) be generated with established
microarray platforms and the number of interrogated
sequences should be >5000, thus excluding custom
platforms that are pathway oriented and will introduce bias
towards given biological process; and 3) the experimental
settings must have ≥10 patients per condition.
The studies that satisfied these criteria are listed in
Table 2. We utilized data from 5 different experimental
settings, which were generated using 4 different microarray
platforms. The specific GEO sample IDs (GSM), which
were used for this study and a brief description of the
experimental settings are listed below:
Baron et al. [4]: GSM103566-67, GSM103610-11, GSM
103616-17, GSM103642-43, GSM103680-81, GSM103684-85,
GSM103700-01, GSM103712-13, GSM103716-17, GSM
Table 1 Gene candidates for skin manifestation of cGVHD




Jun proto-oncogene* JUN 13683 1546 83 16 33
Lymphotoxin beta receptor LTBR 94 93 6 9 0
CD48 molecule CD48 136 275 29 4 0
Cyclin D1 CCND1 7324 424 76 3 1
FBJ murine osteosarcoma viral oncogene
homolog
FOS 15253 836 31 1 10
Interleukin 16 IL16 129 242 2 1 1
CDC-like kinase 1 CLK1 27 0 1 1 0
Matrix metallopeptidase 2 (gelatinase A) MMP2 906 45 30 0 4
DEAD (Asp-Glu-Ala-Asp) box polypeptide 3,
X-linked
DDX3X 57 2 2 0 0
GRB2-associated binding protein 1 GAB1 114 23 1 0 0
FBJ murine osteosarcoma viral oncogene
homolog B
FOSB 522 22 1 0 0
Tumor necrosis factor, alpha-induced
protein 8
TNFAIP8 14 4 1 0 0
Prosaposin PSAP 178 11 0 0 1
SATB homeobox 1 SATB1 146 61 0 0 0
Dual specificity phosphatase 1 DUSP1 392 18 0 0 0
Ubiquitin specific peptidase 18 USP18 71 7 0 0 0
Dnaj (Hsp40) homolog, subfamily B, member 1 DNAJB1 67 7 0 0 0
Elongation factor, RNA polymerase II, 2 ELL2 22 6 0 0 0
Serum/glucocorticoid regulated kinase SGK 211 3 0 0 0
Retinoid X receptor, alpha RXRA 77 3 0 0 0
Zinc finger protein 331 ZNF331 18 2 0 0 0
Protein kinase, AMP-activated, alpha 1
catalytic subunit
PRKAA1 77 1 0 0 0
Methionine sulfoxide reductase B1 SEPX1 5 1 0 0 0
ARP6 actin-related protein 6 homolog (yeast) ACTR6 1 0 0 0 0
Ubiquitin specific peptidase 47 USP47 1 0 0 0 0
*Bolded are genes related to fibroblast proliferation.
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CD4+/CD8+ cells were from 12 donors, whose cells
did not cause cGVHD in a recipient 1 year after
aSCT; GSM103626-27, GSM103630-31, GSM103634-35,
GSM103638-39, GSM103650-51, GSM103668-69, GSM
103678-79, GSM103686-87, GSM103689, GSM103696-97,
GSM103568-69, GSM103570-71, GSM103573, GSM103Table 2 Summary of microarray data used for meta-analysis
Condition Cell type Healthy cells Diseased cells
aSCT CD4/CD8 12/12 10/10
aSCT + cGVHD CD4/CD8 18/17 14/13
Diffuse SSc PBMCs 41 19
Diffuse SSc PBMCs 10 10
Limited SSc PBMCs 10 21584-85, GSM103592-93, GSM103594-95, GSM103604-05,
GSM103704-05, and GSM103707. Their CD4+/CD8+ cells
were from 18 donors, whose cells did cause cGVHD in a
recipient 1 year after aSCT (one CD8+ sample was not re-
ported, see Table 2); GSM103620-21, GSM103640-41,
GSM103710-11, GSM103714-15, GSM103718-19, GSM10
3722-23, GSM103726-27, GSM103652-53, GSM103682-83,GEO ID Microarray platform Author
GSE4624 Canvac Baron et al [4].
GSE4624 Canvac Baron et al. [4]
GSE33463 Illumina Cheadle et al. [13]
GSE22356 Affymetrix Risbano et al. [14]
GSE19617 Agilent Pendergrass et al. [15]
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aSCT patients, who remain cGVHD-free 1 year after aSCT;
GSM103622-23, GSM103624-25, GSM103628-29, GSM10
3632-33, GSM103636-37, GSM103572, GSM103582-83,
GSM103590-91, GSM103618-19, GSM103648-49, GSM10
3666-67, GSM103688, GSM103694-95, GSM103702-03,
and GSM103706. Their CD4+/CD8+ cells were from 14
cGVHD patients, who developed cGVHD 1 year after
aSCT (one CD8+ sample is not reported, see Table 2).
Cheadle et al. [13]: GSM827665-705 – PBMCs were
from 41 healthy controls, and GSM827778-96, PBMCs
from 19 patients with diffuse SSc.
Risbano et al. [14]: GSM556441-50, PBMCs were from
10 healthy controls, and GSM556413-22, PBMCs from
10 patients with diffuse SSc.
Pendergrass et al. [15]: GSM489236-41, GSM489243,
GSM489245-47, PBMCs were from 10 healthy controls,
and GSM489194-98, GSM489200-01, GSM489204, GSM
489207-218, PBMCs from 21 patients with limited SSc.
Linking different microarray platforms
Obtained GSMs were cross-linked based on the GEO
provided Minimum Information About a Microarray
Experiment (MIAME) data as described previously
[16,17]. Briefly, the probe IDs across different microarray
platforms were linked using the Array Information
Library Universal Navigator (AILUN) tool (http://ailun.
stanford.edu) and the probes that remained unmatched
by AILUN were added to the main AILUN created
dataset by matching HUGO-approved gene symbols.
Gene candidate selection
To estimate differences between groups of samples from
aSCT and aSCT + cGVHD patients, and healthy and SSc
patients, raw post-quantitation microarray data was median
trimmed using minimal trim of 1 highest and 1 lowest
expressors. Given the general trend of microarray data
series to have low number of biological replicates, the more
vigorous trimming was not applied, due to the great reduc-
tion of statistical power. The probes without a positive
signal throughout all the experiments were then removed,
and the remaining data were reanalyzed using SAM 2.0
software [18], applying default settings without application
of arbitrary restrictions [19], as described previously [20].
For each gene in every microarray experiment, the d score,
which denotes the standardized change in gene expression
of diseased lymphocytes versus corresponding healthy
lymphocytes, was calculated. Given that the total of
32671 probes were analyzed, the Bonferroni threshold
(P = 1.53 × 10−6) was used for detecting significance.
For eGWAS analysis, 32671 probes from all experiments
were merged into one dataset and significant and not
significant changes counted and [4] evaluated by chi-square
test as described previously [21]. Genes with an absolutevalue of d score ≥2 [17] or an absolute value of fold
change ≥1.2 [22] between healthy and diseased groups
were considered significantly dysregulated.
Molecular signature subtraction
The gene lists for subtraction analysis were generated
using “ranking order” approach. SAM output was ranked
according to the fold change and genes from the top
quartile were considered significantly affected by a
corresponding disease. The subtraction of transcript lists
was conducted using VENNY tool (http://bioinfogp.cnb.
csic.es/tools/venny/index.html). The significance of asso-
ciation of lymphocyte types (CD4+ or CD8+) in cGVHD
samples with the PBMC samples from scleroderma types
(diffuse or limited) was assessed using two tailed T-test.
Given that scleroderma is represented in the GEO
collection by PBMC data only, but knowing that
PBMCs are comprised of up to 60% of CD4+ and up
to 30% of CD8+, we considered it acceptable to directly
compare CD4+ and CD8+ fractions of cGVHD samples
with PBMC samples of SSc patients. Values submitted
to the T-test were first normalized to the total num-
ber of lymphocyte type or scleroderma type, respect-
ively. Association between molecular signatures with
P value <0.05 was considered significant.
Automated literature search
PubMatrix (multiplex literature mining tool) analysis [23]
was conducted as described previously [22]. We restricted
our search to human symbols approved by HUGO Gene
Nomenclature Committee (HGNC), which were enriched
by all aliases and former (discontinued) symbols for
selected candidate genes (http://www.genenames.org). The
symbols with the hyphen and double names separated by a
slash were filtered out. The biomedical literature reference
count for a given gene was represented by the highest num-
ber among HUGO symbol or its aliases. The genes with
number of references N ≥ 5 were considered to have estab-
lished association with cGVHD, 5 >N > 0 were considered
novel (have been noticed during cGVHD studies, but were
not linked to the disease), and N = 0 were considered new.
Pathway analysis
The pathway analysis, which links the most relevant
biological processes to a provided list of candidate
genes, was conducted using the Ingenuity Pathways
Knowledge Base tool (Ingenuity Systems, Inc., Redwood
City, CA.) as described previously [24,25]. Gene symbols
from CD4+ and CD8+ significant gene lists were submitted
to the IPA and analyzed using “Core” tool. Significance of
the identified pathways was tested by the IPA imbedded
Fisher Exact test and expressed as p-value [26]. Pathways,
that were built of 5 or more genes and had p < 0.05 were
considered significant.
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